Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 6:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1247
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1021–1032 of 1,247 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04095364
Site status not listed — check the official record
View directory record Official record
Conditions
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel
Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
883
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Active, not recruiting Phase 3 Interventional

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

NCT03091660
Site status not listed — check the official record
View directory record Official record
Conditions
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Interventions
BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
174
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Recruiting Phase 2 Interventional

Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

NCT05917522
Status at this site: Recruiting
View directory record Official record
Conditions
Kidney Transplant
Interventions
Abatacept, Standard of Care at US Transplant Centers
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

NCT02503423
Site status not listed — check the official record
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
ASTX660
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Recruiting Not applicable Interventional

Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction

NCT06077240
Status at this site: Recruiting
View directory record Official record
Conditions
Smoking, Smoking Behaviors, Nicotine Dependence
Interventions
E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors, E-cigarette with 2.4% Nicotine with Tobacco Flavor Only, E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors, E-cigarette with 5% Nicotine with Tobacco Flavor Only, Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors, Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only, Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors, Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only
Behavioral
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Active, not recruiting Phase 3 Interventional

An Open Label Study of CM-AT for the Treatment of Children With Autism

NCT02649959
Site status not listed — check the official record
View directory record Official record
Conditions
Autism
Interventions
CM-AT
Drug
Lead sponsor
Curemark
Industry
Eligibility
3 Years to 17 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
ARV-471, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Active, not recruiting Not applicable Interventional

Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae

NCT03506308
Site status not listed — check the official record
View directory record Official record
Conditions
Arteriovenous Fistula
Interventions
LUTONIX 035 Drug Coated Balloon PTA Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Recruiting Phase 1 Interventional

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06153251
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
BMS-986453, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Not yet recruiting Phase 2 Interventional

Pilot Study: Effects of Nimodipine on Alcohol Drinking

NCT06900998
Site status not listed — check the official record
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Nimodipine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
Site status not listed — check the official record
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 1, 2026, 6:34 PM EST
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

NCT05735184
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 1, 2026, 6:34 PM EST

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.